U.S. Building Stock News

NYSE:ARW
NYSE:ARWElectronic

Arrow Electronics Remote Lab Service Aims To Deepen Engineering Engagement

Arrow Electronics (NYSE:ARW) has introduced Digital Test Drive, a cloud-based remote engineering service. The service allows users to access and test hardware remotely through secure connections to Arrow’s engineering labs. Digital Test Drive is intended to reduce friction from kit availability, shipping logistics, and on-site setup. Arrow Electronics (NYSE:ARW) operates as a global distributor and solutions provider for electronic components and enterprise computing products. With Digital...
NasdaqCM:VKTX
NasdaqCM:VKTXBiotechs

Viking Therapeutics (VKTX) Valuation Revisited After New VK2735 Phase 2 Obesity Data Spurs Investor Interest

Viking Therapeutics (VKTX) drew fresh attention after presenting new Phase 2 data on its oral obesity drug candidate VK2735 at the European Congress on Obesity. The company highlighted weight loss efficacy, dose response, and safety over a 13-week period. See our latest analysis for Viking Therapeutics. Despite the fresh VK2735 data, Viking Therapeutics’ share price return has been mixed recently, with a 1-day gain of 1.26% and the 30-day share price return down 9.41%. However, the 1-year...
NasdaqGS:ONB
NasdaqGS:ONBBanks

Assessing Old National Bancorp (ONB) Valuation After Recent Share Price Weakness

Why Old National Bancorp (ONB) is on investors’ radar today Old National Bancorp (ONB) has drawn fresh attention after recent trading left the stock with a year to date gain of 3.9% and a 1 year total return of 6.5%, despite softer recent returns. See our latest analysis for Old National Bancorp. Recent trading has been softer, with the share price down 2.94% over the last day and 4.60% over the past week. However, the 3 year total shareholder return of 96.69% and 5 year total shareholder...
NasdaqGM:ARRY
NasdaqGM:ARRYElectrical

How Record Backlog, New Tracker Tech And Leadership Hire At Array Technologies (ARRY) Has Changed Its Investment Story

Array Technologies, Inc. recently reported Q1 2026 results showing sales of US$223.41 million and net income of US$2.00 million, alongside a record US$2.40 billion order book, reaffirmed full‑year guidance, and continued international expansion supported by its new DuraTrack D2S tracker. The company also hired former First Solar executive Charlie Wickersham as Senior Vice President of Technology, underscoring a stronger focus on advancing its tracker hardware and SmartTrack software to...
NasdaqGS:FRMI
NasdaqGS:FRMISpecialized REITs

Fermi Leadership Showdown Raises Questions Over Valuation And Future Direction

Fermi (NasdaqGS:FRMI) is facing an escalating leadership and governance clash after the Board terminated former CEO Toby Neugebauer for cause. Neugebauer is now seeking to replace the Board and push for a company sale, moves that the current directors have publicly rejected. Major shareholder Caddis Capital has aligned with the Board, opposing a forced sale and backing the existing strategic direction. For investors following Fermi (NasdaqGS:FRMI), this governance fight sits on top of...
NYSE:MPC
NYSE:MPCOil and Gas

Is Marathon Petroleum (MPC) Still Attractively Priced After Its Strong 2024 Share Price Rally

Wondering whether Marathon Petroleum at US$251.99 still offers value, or if most of the upside is already in the price? This article walks through what the current share price could be implying. The stock has been strong over multiple periods, with a decline of 3.3% over the last week, a 13.2% gain over the last month, a 52.6% return year to date and a 58.1% return over the past year. The three year return sits at 150.1%, and the five year return is a very large gain. Recent coverage has...
NasdaqGS:ERAS
NasdaqGS:ERASBiotechs

The Bull Case For Erasca (ERAS) Could Change Following New KEYTRUDA Alliance And ERAS-0015 Focus Shift

Erasca, Inc. recently reported a first-quarter 2026 net loss of US$183.44 million, driven largely by a US$150 million in-process R&D charge to expand global rights to its pan-RAS candidate ERAS-0015, while also securing a clinical trial collaboration and supply agreement with Merck to test ERAS-0015 with KEYTRUDA in RAS-mutant solid tumors. These developments, alongside early efficacy signals for ERAS-0015 and Merck supplying pembrolizumab at no cost, highlight how Erasca is concentrating...
NYSE:INFQ
NYSE:INFQTech

Infleqtion Nvidia Tie Up Reframes Quantum AI Growth Story For Investors

Infleqtion (NYSE:INFQ) has been selected by Nvidia to support new Ising AI models, signaling a broader role in quantum enabled computing. The company is expanding its work with government and enterprise partners alongside the Nvidia collaboration. These developments follow Infleqtion's recent public listing and planned participation in upcoming industry symposiums. For investors watching quantum computing, Infleqtion now trades around $13.10, with the stock down 23.6% year to date but up...
NasdaqGM:SHLS
NasdaqGM:SHLSElectrical

Why Shoals Technologies Group (SHLS) Is Up 6.2% After Hiking 2026 Revenue Guidance And Backlog Outlook

Shoals Technologies Group, Inc. reported past first-quarter 2026 results with sales of US$140.56 million versus US$80.36 million a year earlier, while remaining near breakeven with a net loss of about US$0.30 million. Alongside this, the company raised its full-year 2026 revenue guidance to US$600 million–US$640 million and highlighted a record US$758 million backlog and awarded orders, underscoring strong underlying demand despite higher costs. With Shoals now guiding to higher 2026...
NYSE:MD
NYSE:MDHealthcare

Pediatrix Medical Group (MD) Is Up 13.7% After Beating EPS and Reaffirming EBITDA Outlook - Has The Bull Case Changed?

Pediatrix Medical Group, Inc. reported past first-quarter 2026 results with sales of US$476.2 million and net income of US$29.57 million, alongside higher basic and diluted earnings per share from continuing operations than a year earlier. The company’s stronger-than-expected adjusted EPS, reaffirmed full-year adjusted EBITDA outlook, and benefits from pricing and payer mix highlight improving operational execution despite modest volume declines. We’ll now examine how reaffirmed full-year...
NYSE:LEU
NYSE:LEUOil and Gas

Raised 2026 Outlook and Federal Project Pipeline Could Be A Game Changer For Centrus Energy (LEU)

Centrus Energy Corp. reported past first-quarter 2026 results with revenue of US$76.7 million, net income of US$10.0 million, and diluted EPS of US$0.45, while also raising its full‑year 2026 revenue outlook to a range of US$450.0 million to US$500.0 million. Alongside the improved guidance, the company pointed to a large order backlog, progress on a US$560.0 million Oak Ridge centrifuge expansion, and the possibility of a US$900.0 million HALEU award from the U.S. Department of Energy,...
NasdaqGS:GTX
NasdaqGS:GTXAuto Components

Is It Too Late To Consider Garrett Motion (GTX) After A 152% One Year Surge?

Investors may be wondering if Garrett Motion at around US$29.57 is still offering value after a strong run, or if they might be late to the story. The stock has delivered returns of 13.1% over the past week, 51.8% over the past month, 70.1% year to date and 152.2% over the past year, putting it firmly on many investors' radars. Recent coverage has focused on Garrett Motion's role in the Auto Components sector and how investors are reassessing companies involved in vehicle technology and...
NYSE:IONQ
NYSE:IONQTech

IonQ Sustainability Partnership Highlights Urban Planning Use Case And Valuation Tension

IonQ (NYSE:IONQ) has been selected to provide quantum computing systems for the three year Harmonious Urban Growth sustainability partnership. The project, run with The King’s Foundation and FormationQ, will use IonQ’s quantum optimisation technology as its computational backbone. The collaboration focuses on applying quantum computing to urban planning, infrastructure and sustainability use cases. IonQ enters this partnership with strong recent stock performance, with the shares at $55.87...
NasdaqGS:CRSR
NasdaqGS:CRSRTech

Assessing Corsair Gaming (CRSR) Valuation After Profit Return And Recent Earnings Turnaround

Corsair Gaming earnings and new share registration draw investor focus Corsair Gaming (CRSR) has reported a shift from a net loss to net income in its latest quarter, and has filed a shelf registration for common stock related to its employee stock ownership plan. See our latest analysis for Corsair Gaming. The latest quarter’s swing to net income has come alongside strong recent momentum in the stock, with a 30-day share price return of 31.81% and a 90-day share price return of 51.21%...
NYSE:AEM
NYSE:AEMMetals and Mining

Is It Time To Reassess Agnico Eagle Mines (AEM) After An 86% One-Year Surge?

If you are wondering whether Agnico Eagle Mines at US$197.05 is still offering value after a strong run, it helps to step back and look at what the recent numbers and news are really telling you about the stock. The share price has delivered a 10.6% gain over the past week, while the stock is down 9.9% over the past month, up 15.6% year to date and up 86.1% over the last year. These moves can change how the market is thinking about both upside potential and risk. Recent coverage has focused...
NasdaqGS:LNT
NasdaqGS:LNTElectric Utilities

Alliant Energy (LNT) Valuation Check After Q1 Earnings Beat And Reaffirmed 2026 Guidance

Alliant Energy (LNT) shares are in focus after the utility reported first quarter 2026 earnings and reaffirmed its full year earnings guidance, giving investors fresh data on revenue, profits, and ongoing EPS expectations. See our latest analysis for Alliant Energy. The first quarter earnings and reaffirmed 2026 EPS guidance come after a period where the share price has a year to date gain of 10.67%, while the 1 year total shareholder return is 23.83%, suggesting that momentum has been...
NYSE:USB
NYSE:USBBanks

Is It Too Late To Consider U.S. Bancorp (USB) After Its Strong One Year Rally?

Wondering if U.S. Bancorp at around US$54.48 is still offering value, or if most of the easy gains are already behind it. The stock is up 1.0% year to date and 28.0% over the past year, even though it has slipped about 2.0% over the past week and 2.1% over the past month. This suggests the recent pullback sits against a much stronger longer term return profile. Recent coverage has focused on U.S. Bancorp's position among large U.S. banks and how investors are reassessing risk and reward for...
NasdaqGS:ICHR
NasdaqGS:ICHRSemiconductor

A Look At Ichor Holdings (ICHR) Valuation After Strong Recent Share Price Gains

Recent performance snapshot Ichor Holdings (ICHR) has drawn attention after a strong run in recent periods, with the stock up 27% over the past month and 54% over the past 3 months, and a 180% total return over 1 year. Those moves sit alongside reported annual revenue of US$959.3m and a net loss of US$50.7m, prompting investors to consider how the recent share performance aligns with the company’s current earnings profile. See our latest analysis for Ichor Holdings. The recent run, with a 27%...
NYSE:GEV
NYSE:GEVElectrical

Assessing GE Vernova (GEV) Valuation After Strong Recent Share Price Momentum

Recent performance snapshot With no single headline event in focus, GE Vernova (GEV) has drawn attention after a recent run that includes a gain of about 8% over the past month and roughly 30% in the past 3 months. See our latest analysis for GE Vernova. That recent 30.2% 3 month share price return, alongside a year to date share price return of 57.8% and a 1 year total shareholder return of about 148%, points to momentum still building around GE Vernova at a last close of US$1,071.98. If you...
NYSE:MUX
NYSE:MUXMetals and Mining

Assessing McEwen (MUX) Valuation After Profitable Q1 And Los Azules Growth Plans

What McEwen’s Q1 earnings mean for investors now McEwen (MUX) reported a profit in Q1 2026, supported by higher revenue that was associated with firmer gold and silver prices and improved operations. The company also highlighted its production growth objectives and reported progress at the Los Azules copper project. See our latest analysis for McEwen. The Q1 earnings news has arrived after a strong run, with McEwen’s share price up 23.69% over the past week and 40.04% year to date. Its 1 year...
NYSE:FDS
NYSE:FDSCapital Markets

FactSet And Valutico Link Private Market Valuations To Support FDS Story

FactSet Research Systems (NYSE:FDS) has launched a new partnership with Valutico to integrate valuation workflows for private capital markets. The collaboration connects portfolio monitoring, valuation modeling, and reporting in a single system for private asset investors. The move addresses growing industry pressure for more frequent and transparent private market valuations. FactSet Research Systems, trading at $215.92, has faced a challenging share price path, with the stock down 24.2%...
NYSE:AWK
NYSE:AWKWater Utilities

Assessing American Water Works Company (AWK) Valuation After Customer Satisfaction And Water Quality Updates

American Water Works Company (AWK) is back in focus after J.D. Power accolades for customer satisfaction, fresh water quality reports confirming regulatory compliance, and updates on infrastructure and community investment across its regional subsidiaries. See our latest analysis for American Water Works Company. The recent run of customer satisfaction awards, water quality confirmations, and community investment updates comes as the stock trades at US$127.65, with a 90 day share price return...
NasdaqCM:CPRX
NasdaqCM:CPRXBiotechs

Catalyst Pharmaceuticals (CPRX) Q1 EPS Beat Reinforces High Margin Bull Narratives

Catalyst Pharmaceuticals (CPRX) opened Q1 2026 with total revenue of US$149.4 million and basic EPS of US$0.52, setting a clear marker for how the year is starting. The company has seen quarterly revenue range from US$141.4 million in Q1 2025 to US$152.6 million in Q4 2025, while basic EPS moved between US$0.43 and US$0.47 over that period, giving you a solid view of how the top and bottom line have been tracking into the latest print. With a trailing net profit margin of 37.1% and earnings...
NasdaqGM:RYTM
NasdaqGM:RYTMBiotechs

New Setmelanotide Data Shapes Rhythm Pharmaceuticals Obesity Growth Story

Rhythm Pharmaceuticals presented new clinical data on setmelanotide in adults with acquired hypothalamic obesity at the 2026 European Congress of Endocrinology. The data showed meaningful BMI reductions and improved cardiometabolic outcomes in treated adults. These findings follow recent pediatric efficacy results shared at the PES Annual Meeting, adding to the evidence base for IMCIVREE across different patient groups. The updates arrive shortly after regulatory approvals and commercial...